MX2024009309A - Anticuerpo contra btla y sus usos. - Google Patents
Anticuerpo contra btla y sus usos.Info
- Publication number
- MX2024009309A MX2024009309A MX2024009309A MX2024009309A MX2024009309A MX 2024009309 A MX2024009309 A MX 2024009309A MX 2024009309 A MX2024009309 A MX 2024009309A MX 2024009309 A MX2024009309 A MX 2024009309A MX 2024009309 A MX2024009309 A MX 2024009309A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody against
- btla
- against btla
- antigen
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Transplantation (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022075109 | 2022-01-29 | ||
| PCT/CN2023/073699 WO2023143564A1 (en) | 2022-01-29 | 2023-01-29 | Antibody against btla and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009309A true MX2024009309A (es) | 2024-08-27 |
Family
ID=87470720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009309A MX2024009309A (es) | 2022-01-29 | 2023-01-29 | Anticuerpo contra btla y sus usos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250388673A1 (enExample) |
| EP (1) | EP4469482A4 (enExample) |
| JP (1) | JP2025504543A (enExample) |
| KR (1) | KR20240139083A (enExample) |
| CN (1) | CN118871465A (enExample) |
| AR (1) | AR128377A1 (enExample) |
| AU (1) | AU2023212896A1 (enExample) |
| CA (1) | CA3250219A1 (enExample) |
| IL (1) | IL314579A (enExample) |
| MX (1) | MX2024009309A (enExample) |
| TW (1) | TW202340253A (enExample) |
| WO (1) | WO2023143564A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2097447A4 (en) * | 2006-11-15 | 2010-12-29 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE |
| BR112012007875A2 (pt) * | 2009-07-31 | 2016-11-22 | Medarex Inc | anticorpos totalmente humanos para btla |
| MX2018010295A (es) * | 2016-02-26 | 2019-06-06 | Inst Nat Sante Rech Med | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. |
| CN110790837A (zh) * | 2018-08-02 | 2020-02-14 | 上海君实生物医药科技股份有限公司 | 抗btla抗体 |
-
2023
- 2023-01-29 CN CN202380023757.XA patent/CN118871465A/zh active Pending
- 2023-01-29 CA CA3250219A patent/CA3250219A1/en active Pending
- 2023-01-29 AU AU2023212896A patent/AU2023212896A1/en active Pending
- 2023-01-29 WO PCT/CN2023/073699 patent/WO2023143564A1/en not_active Ceased
- 2023-01-29 KR KR1020247029189A patent/KR20240139083A/ko active Pending
- 2023-01-29 IL IL314579A patent/IL314579A/en unknown
- 2023-01-29 US US18/833,730 patent/US20250388673A1/en active Pending
- 2023-01-29 JP JP2024544441A patent/JP2025504543A/ja active Pending
- 2023-01-29 EP EP23746441.7A patent/EP4469482A4/en active Pending
- 2023-01-29 MX MX2024009309A patent/MX2024009309A/es unknown
- 2023-01-30 AR ARP230100205A patent/AR128377A1/es unknown
- 2023-01-30 TW TW112103090A patent/TW202340253A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023212896A1 (en) | 2024-08-22 |
| WO2023143564A1 (en) | 2023-08-03 |
| EP4469482A4 (en) | 2026-05-06 |
| AR128377A1 (es) | 2024-04-24 |
| TW202340253A (zh) | 2023-10-16 |
| US20250388673A1 (en) | 2025-12-25 |
| IL314579A (en) | 2024-09-01 |
| JP2025504543A (ja) | 2025-02-12 |
| CA3250219A1 (en) | 2023-08-03 |
| EP4469482A1 (en) | 2024-12-04 |
| KR20240139083A (ko) | 2024-09-20 |
| CN118871465A (zh) | 2024-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20076683A (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| MX2023014458A (es) | Anticuerpos anti-ccr8 y usos de los mismos. | |
| EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| CL2024002250A1 (es) | Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria. | |
| MX2021005323A (es) | Metodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn. | |
| CR11030A (es) | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos | |
| BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
| MX2022002672A (es) | Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo. | |
| EA202091747A1 (ru) | Составы антитела b7-h4 | |
| JOP20210286A1 (ar) | جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr | |
| MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. | |
| ECSP22015044A (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
| AR128031A1 (es) | Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden | |
| MX2022008421A (es) | Anticuerpo anti-galectina-9 y usos del mismo. | |
| BR112023006989A2 (pt) | Anticorpos biespecíficos anti-pd-1/cd40 e usos dos mesmos | |
| WO2022174103A3 (en) | Monoclonal antibodies specific for human ror1 | |
| CL2022002829A1 (es) | Anticuerpo anti-ox40 y usos del mismo | |
| MX2024014232A (es) | Anticuerpo anti-b7h3 y usos del mismo | |
| CO2022010244A2 (es) | Anticuerpos anti-e-selectina, composiciones y métodos de uso | |
| PE20181199A1 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
| MX2022005862A (es) | Metodos de tratamiento de anemia hemolitica autoinmune caliente mediante el uso de anticuerpos anti-fcrn. | |
| MX2024008933A (es) | Anticuerpos anti-musk para uso en el tratamiento de trastornos neuromusculares. | |
| MX2024009309A (es) | Anticuerpo contra btla y sus usos. | |
| MX2025007017A (es) | Anticuerpo que se une a piroglutamato de beta amiloide que inicia en la posicion 3 (abetape3) |